Amir Sultan1, Chimaobi M Anugwom2, Zerihun Wondifraw1, Grace A Braimoh3, Abate Bane1,4, Jose D Debes2,3,5. 1. College of Health Sciences, Addis Ababa University , Addis Ababa, Ethiopia. 2. Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota , Minneapolis, MN, USA. 3. Department of Medicine, Division of Gastroenterology, Hennepin Healthcare , Minneapolis, MN, USA. 4. Adera Gastroenterology and Hepatology Center , Addis Ababa, Ethiopia. 5. Division of Infectious Diseases, Department of Medicine, University of Minnesota , Minneapolis, MN, USA.
Abstract
PURPOSE: To evaluate the characteristics and response to therapy for HCC in sub-Saharan Africa. PATIENTS AND METHODS: We retrospectively evaluated demographic, clinical and outcome variables of HCC in a referral clinic in Ethiopia from 2016 to 2018. Survival assessment was performed using the Mann-Whitney test. Associations between categorical variables was assessed using Pearson Chi-square test. RESULTS: We report 46 HCC cases with a median age of 54 years (IQR 45-62) and 50% female. Viral hepatitis was the most common underlying etiology, with 41% of subjects infected with hepatitis B virus (HBV) and 45% with hepatitis C. The median MELD was 12 (IQR 8-17), we found no association between survival and a MELD score </> 15, regardless of underlying disease (pr=0.61, p>0.05). 31% of individuals underwent supportive treatment with a median survival of 27 days (IQR 19-181), 18% used Sorafenib (median survival of 94 days, IQR 24-121), and trans-arterial chemoembolization (TACE) was utilized in 16% (median survival of 352 days, IQR 30-436). HBV cases were diagnosed younger (31% before the age of 40) and those on Tenofovir had a longer median survival than those off Tenofovir (121 vs 34 days). CONCLUSION: Our study found that antiviral treatment of HBV infection was associated with longer survival in HCC. Furthermore, Sorafenib seemed beneficial in patients that used this modality and NLR was a good prognostic factor.
PURPOSE: To evaluate the characteristics and response to therapy for HCC in sub-Saharan Africa. PATIENTS AND METHODS: We retrospectively evaluated demographic, clinical and outcome variables of HCC in a referral clinic in Ethiopia from 2016 to 2018. Survival assessment was performed using the Mann-Whitney test. Associations between categorical variables was assessed using Pearson Chi-square test. RESULTS: We report 46 HCC cases with a median age of 54 years (IQR 45-62) and 50% female. Viral hepatitis was the most common underlying etiology, with 41% of subjects infected with hepatitis B virus (HBV) and 45% with hepatitis C. The median MELD was 12 (IQR 8-17), we found no association between survival and a MELD score </> 15, regardless of underlying disease (pr=0.61, p>0.05). 31% of individuals underwent supportive treatment with a median survival of 27 days (IQR 19-181), 18% used Sorafenib (median survival of 94 days, IQR 24-121), and trans-arterial chemoembolization (TACE) was utilized in 16% (median survival of 352 days, IQR 30-436). HBV cases were diagnosed younger (31% before the age of 40) and those on Tenofovir had a longer median survival than those off Tenofovir (121 vs 34 days). CONCLUSION: Our study found that antiviral treatment of HBV infection was associated with longer survival in HCC. Furthermore, Sorafenib seemed beneficial in patients that used this modality and NLR was a good prognostic factor.
Authors: Nimzing G Ladep; Olufunmilayo A Lesi; Pantong Mark; Maud Lemoine; Charles Onyekwere; Mary Afihene; Mary Me Crossey; Simon D Taylor-Robinson Journal: World J Hepatol Date: 2014-11-27
Authors: Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach Journal: Hepatology Date: 2018-08 Impact factor: 17.425
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506
Authors: Ju Dong Yang; Essa A Mohamed; Ashraf O Abdel Aziz; Hend I Shousha; Mohamed B Hashem; Mohamed M Nabeel; Ahmed H Abdelmaksoud; Tamer M Elbaz; Mary Y Afihene; Babatunde M Duduyemi; Joshua P Ayawin; Adam Gyedu; Marie-Jeanne Lohouès-Kouacou; Antonin W Ndjitoyap Ndam; Ehab F Moustafa; Sahar M Hassany; Abdelmajeed M Moussa; Rose A Ugiagbe; Casimir E Omuemu; Richard Anthony; Dennis Palmer; Albert F Nyanga; Abraham O Malu; Solomon Obekpa; Abdelmounem E Abdo; Awatif I Siddig; Hatim M Y Mudawi; Uchenna Okonkwo; Mbang Kooffreh-Ada; Yaw A Awuku; Yvonne A Nartey; Elizabeth T Abbew; Nana A Awuku; Jesse A Otegbayo; Kolawole O Akande; Hailemichael M Desalegn; Abidemi E Omonisi; Akande O Ajayi; Edith N Okeke; Mary J Duguru; Pantong M Davwar; Michael C Okorie; Shettima Mustapha; Jose D Debes; Ponsiano Ocama; Olufunmilayo A Lesi; Emuobor Odeghe; Ruth Bello; Charles Onyekwere; Francis Ekere; Rufina Igetei; Mitchell A Mah'moud; Benyam Addissie; Hawa M Ali; Gregory J Gores; Mark D Topazian; Lewis R Roberts Journal: Lancet Gastroenterol Hepatol Date: 2016-12-03
Authors: Chimaobi M Anugwom; Manon Allaire; Sheikh Mohammad Fazle Akbar; Amir Sultan; Steven Bollipo; Angelo Z Mattos; Jose D Debes Journal: Hepatoma Res Date: 2021-03-26